Table 1. Participant Characteristics.
Except otherwise indicated, data represent N (%) of participants.
| Variable | Total (n=80) | HIV Infected
|
Not HIV (n=34) | |
|---|---|---|---|---|
| HIV/PI (n=25) | HIV/Not PI (n=21) | |||
| Male sex | 73 (91) | 24 (96) | 19 (90) | 30 (88) |
| Race or ethnicity | ||||
| White non-Hispanic | 60 (75) | 20 (80) | 15 (71) | 25 (74%) |
| Hispanic (regardless of race) | 15 (19) | 3 (12) | 4 (19) | 8 (24%) |
| Other/unknown | 5 (6) | 2 (8) | 2 (10) | 1 (3) |
| Age, median (IQR), y | 41 (36, 45) | 41 (37, 45) | 41 (38, 45) | 40 (36, 45) |
| BMI, median (IQR), kg/m2 | 24.7 (23.4, 27.2) | 24.7 (23.4, 27.6) | 24.4 (23.4, 26.6) | 24.8 (23.7, 27.7) |
| Waist circumference ≥ 90 cma | 36 (46) | 14 (58) | 7 (33) | 15 (44) |
| Waist-to-Hip Ratio, median (IQR) | 0.90 (0.85, 0.93) | 0.93 (0.91, 0.95) | 0.90 (0.87, 0.93) | 0.89 (0.83, 0.92) |
| Any statin use | 7 (9) | 6 (24) | 1 (5) | 0 (0) |
| Metabolic parameters | ||||
| Fasting blood glucose, median (IQR), mg/dL | 86 (79, 93) | 87 (81, 94) | 84 (81, 92) | 86 (75, 92) |
| Total cholesterol ≥ 200 mg/dL | 38 (48) | 19 (76) | 6 (29) | 13 (38) |
| Direct LDL cholesterol ≥ 100 mg/dLb | 55 (69) | 19 (76) | 13 (62) | 23 (68) |
| HDL cholesterol < 35 mg/dL | 18 (23) | 5 (20) | 6 (29) | 7 (21) |
| Triglycerides ≥ 150mg/dL | 31 (39) | 15 (60) | 7 (33) | 9 (26) |
| Non-HDL cholesterol, median (IQR), mg/dL | 147.5 (122.0, 185.5) | 187 (144, 210) | 129 (118, 151) | 145 (122, 168) |
| Insulin, median (IQR), mU/Lc | 6.4 (5.1, 8.0) | 6.9 (5.8, 13.0) | 5.7 (4.6, 7.8) | 6.1 (5.0, 7.7) |
| Inflammation parameters | ||||
| hs-CRP, median ( IQR), mg/Lc | 1.00 (0.50, 2.10) | 1.40 (0.80, 3.30) | 0.90 (0.40, 3.40) | 0.90 (0.50, 1.70) |
| Homocysteine, median (IQR), μmol/Lc | 8.95 (7.40, 10.10) | 8.90 (7.40, 13.80) | 7.45 (6.25, 8.35) | 9.70 (8.70, 11.00) |
| HIV disease-related parameters | ||||
| Baseline CD4+ T-cell count, median (IQR), cells/mm3 | 515 (344, 679) | 559 (395, 707) | 469 (329, 642) | … |
| Nadir CD4+ T-cell count ≤ 200 cells/mm3 d | 17 (38) | 9 (38) | 8 (38) | … |
| Duration of PI use, median ( IQR), wk | 126 (0, 244) | 238 (152, 259) | 0 (0, 0) | … |
| Baseline sCD14, median (IQR), μg/mL | 1.74 (1.08, 2.57) | 2.36 (1.69, 3.15) | 2.08 (1.64, 2.70) | 1.19 (0.95, 1.79) |
| Baseline CIMT, median (IQR), μm e | 695 (621, 762) | 752 (612, 780) | 697 (671, 747) | 683 (624, 756) |
a
Because of missing data, the sample sizes were n=79, n=24, n=21, and n=34, respectively.
b
Because of missing data, the sample sizes were n=78, n=23, n=21, and n=34, respectively.
c
Because of missing data, the sample sizes were n=74, n=23, n=20, and n=31, respectively.
d
Because of missing data, the sample sizes were n=45, n=24, and n=21, respectively.
e
Kruskal-Wallis Test for between group differences in baseline CIMT (p=0.74).